[THE INVESTOR] On Sept. 13 Whanin Pharm (016580) slightly edged down 0.63% to 15,650 won (US$13.98). It had declined 6.87% through the past month. Standard deviation, the risk index for stock price, was 1.9% on the same period of time over one month.

Compared with its close competitors within the same industry, KOSPI, even though the monthly earnings rate of Whanin Pharm was negative, its volatility for one month was lower than that of its peer group. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -3.6%. With low volatility, the return-on-risk remained around the average of its peer group. In spite of that, the return-on-risk is much better than the industrial mean, -3.8, and thus the industrial comparison performance was positive.